During 13.1 months follow-up, atrial fibrillation recurred in 59.3% of patients, which was associated with older age (60.4 vs 55.3 years, P=0.022) and lower ACE-I/ARB use (27.0% vs 50.0%, P=0.025).
Cohort (n=81)
What are the clinical and serological predictors of failed electrical cardioversion and atrial fibrillation recurrence in patients with AF?
Older age, spontaneous echo contrast, under-utilization of RAAS inhibitors, and specific serological markers (high TGF-beta, low SDF-1alpha) predict failed cardioversion or AF recurrence.
AIMS: Although electrical cardioversion (CV) is effective in restoring sinus rhythm in patients with atrial fibrillation (AF), AF frequently recurs in spite of antiarrhythmic medications. We investigated the predictors of failed CV and AF recurrence after successful CV. METHODS AND RESULTS: In 81 patients (M:F = 63:18, 59.1 +/- 10.5 years old) with AF who underwent CV, clinical, image, and CV findings (energy requirement, immediate recurrence of AF 60 years, SEC, under-utilization of ACE-I/ARB or spironolactone, and low plasma levels of SDF-1alpha. High plasma level of TGF-beta predicts failed CV.
Kim et al. (Mon,) conducted a cohort in Atrial fibrillation (n=81). Clinical, echocardiographic, and serological risk factors vs. Patients without these risk factors was evaluated on Failed electrical cardioversion and atrial fibrillation recurrence. During 13.1 months follow-up, atrial fibrillation recurred in 59.3% of patients, which was associated with older age (60.4 vs 55.3 years, P=0.022) and lower ACE-I/ARB use (27.0% vs 50.0%, P=0.025).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: